CJC-1295 (no DAC)
100 mcg · Daily or EOD
Evidence
- Human Studies
- 6
- Animal Studies
- 15
- Clinical Status
- Off-label
- Confidence
- Low
- Long-Term Safety
- Limited — most human GHRH-analogue safety data comes from related approved drugs (e.g. tesamorelin), not this specific compound
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A growth hormone-releasing hormone (GHRH) analogue without the DAC extension that longer-acting versions use, giving it a short half-life (~30 min) and a pulsatile GH-release pattern closer to natural physiology. Often stacked with a GHRP like Ipamorelin.
Common Protocols
- 100 mcg daily or every other day, subcutaneous, often paired with Ipamorelin
- Short half-life means timing (e.g. before bed, fasted) matters more than with DAC-modified versions
Side Effects
- Injection site reaction
- Flushing or mild headache reported anecdotally
- Water retention possible from GH elevation
Interactions
- Combining with other GH secretagogues compounds both effect and risk
Practical Details
- Cost
- $
- Typical Vial Size
- 2 mg
- Storage
- Refrigerate after reconstitution
Research Links
GHRH analogue; stack with Ipamorelin